Pluristem Therapeutics Inc. (NasdaqCM: PSTI; TASE: PLTR) is a developer of placenta-based cell therapies. The Company's patented PLX (PLacental eXpanded) cells are a drug delivery platform that releases a cocktail of therapeutic proteins in response to a host of local and systemic inflammatory and ischemic diseases. PLX cells are grown using the company’s proprietary 3D micro-environmental technology and are an “off-the-shelf” product that requires no tissue matching prior to administration. Pluristem is focusing on the use of PLX cells administered locally to treat systemic diseases and potentially obviating the need to use the intravenous route. Data from two phase I/II studies indicate that Pluristem’s first PLX product candidate, PLX-PAD, is safe and potentially effective for the treatment of end stage peripheral artery disease when given locally. Additionally, Pluristem is developing PLX-PAD for cardiac ischemia, PLX-BMP for Acute Radiation Exposure, Bone Marrow Transplant Failure and Chemotherapy induced Bone Marrow Aplasia, PLX-ORTHO for orthopedic indications and PLX-PAH for Pulmonary Hypertension in collaboration with United Therapeutics.
Market Capitalization: $186.0M
Current Revenue: None yet
Cash Burn: Approximately $11M
Cash and Liquid Investments to Current Liabilities: $43M/$2M
Clinical Status: Planning multinational Phase II/III study CLI under the FDA and the EMA
Planning Phase II study for Intermittent Claudication
Download Pluristem Company Brochure (PDF).
Stem Cell Digest Posts on Pluristem:
June 19, 2009 - European Regulatory Approval for Placental-Derived Stem Cell Clinical Trial
July 31, 2012 - Stem Cell Stocks: Pluristem Therapeutics And Lung Disease
Comments